为什么眼科疾病焦点公司Kala Bio的股票在周一暴跌？-动脉网

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

benzinga 等信源发布 2025-09-29 12:00



可切换为仅中文







Kala Bio Inc.

卡拉生物公司

(NASDAQ:

（纳斯达克：

KALA

卡拉

) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.

）周一，由于该公司暂停了针对特定眼部疾病的实验性治疗的开发，其股票下跌。

The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from

根据数据显示，该公司的成交量为1404万，而平均成交量为21.647万。

Benzinga Pro

本辛加专业版

。

On Monday, the company announced that its CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect (PCED) did not meet the primary endpoint of complete healing of PCED as measured by

周一，该公司宣布其KPI-012用于持续性角膜上皮缺损（PCED）的CHASE 2b期试验未达到以PCED完全愈合为主要终点的测量标准。

corneal fluorescein staining

角膜荧光素染色

。

A persistent corneal epithelial defect is a non-healing area of the outermost layer of the cornea that fails to heal within the typical two-week timeframe, often due to underlying conditions such as limbal stem cell deficiency, diabetes, or neurotrophic keratopathy.

持续性角膜上皮缺损是指角膜最外层在通常两周的时间内未能愈合的区域，通常是由于边缘干细胞缺乏、糖尿病或神经营养性角膜病等基础疾病所致。

The CHASE trial also failed to achieve statistical significance for key secondary efficacy endpoints and did not show any meaningful difference between either KPI-012 treatment arm and the placebo arm.

CHASE 试验也未能在关键的次要疗效终点上达到统计学意义，并且未显示 KPI-012 治疗组与安慰剂组之间存在任何有意义的差异。

Based on the CHASE trial results, KALA plans to cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform. KALA plans to evaluate its strategic options and, as part of this evaluation, engage in discussions with its secured lender. In the interim, the company plans to take steps to preserve cash, including by reducing the workforce and implementing other cost-saving measures..

基于CHASE试验结果，KALA计划停止KPI-012及其间充质干细胞分泌组（MSC-S）平台的开发。KALA计划评估其战略选择，并作为评估的一部分，与其担保贷款方进行讨论。在此期间，公司计划采取措施保留现金，包括缩减员工规模和实施其他成本节约措施。

As of June 30, KALA had cash and cash equivalents of $31.9 million. Based on its current plans, KALA anticipates that its cash resources as of June 30, will enable it to fund operations into the

截至6月30日，KALA拥有3190万美元的现金及现金等价物。根据其当前计划，KALA预计截至6月30日的现金资源将使其能够为运营提供资金直到

first quarter of 2026

2026年第一季度

。

Price Action:

价格行为:

KALA stock is down 91.44% at $1.63 at the last check on Monday.

周一最后一次检查时，KALA股票下跌了91.44%，股价为1.63美元。

加载中...